Cardiome Pharma (CRME) Given a $5.00 Price Target at Canaccord Genuity
Cardiome Pharma (NASDAQ:CRME) (TSE:COM) received a $5.00 target price from equities researchers at Canaccord Genuity in a report released on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity’s target price would suggest a potential upside of 170.27% from the company’s previous close.
Other research analysts also recently issued reports about the company. HC Wainwright set a $10.00 price objective on Cardiome Pharma and gave the company a “buy” rating in a research note on Wednesday. Mackie raised Cardiome Pharma to a “buy” rating in a research note on Friday, December 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $5.67.
CRME stock opened at $1.85 on Wednesday. Cardiome Pharma has a 52 week low of $1.29 and a 52 week high of $4.84. The company has a quick ratio of 4.71, a current ratio of 5.52 and a debt-to-equity ratio of 1.67. The company has a market capitalization of $62.00, a price-to-earnings ratio of -2.06 and a beta of 0.65.
TRADEMARK VIOLATION WARNING: “Cardiome Pharma (CRME) Given a $5.00 Price Target at Canaccord Genuity” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.watchlistnews.com/cardiome-pharma-crme-given-a-5-00-price-target-at-canaccord-genuity/1955742.html.
About Cardiome Pharma
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.
Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.